Biogen Amends Denali Therapeutics Stake Filing
Ticker: BIIB · Form: SC 13G/A · Filed: 2024-02-12T00:00:00.000Z
Sentiment: neutral
Topics: ownership-change, amendment, institutional-investor
TL;DR
**Biogen just updated its Denali stake, watch for ownership changes!**
AI Summary
Biogen Inc. filed an amended SC 13G/A on February 12, 2024, indicating a change in its beneficial ownership of Denali Therapeutics Inc. common stock as of December 31, 2023. This filing, an amendment to a previous Schedule 13G, signals that Biogen's stake in Denali has likely changed, which is important for investors as it could reflect Biogen's evolving strategic interest or financial position regarding Denali, potentially influencing market perception of Denali's future prospects.
Why It Matters
This filing updates Biogen's reported ownership in Denali Therapeutics, which can signal shifts in strategic partnerships or investment priorities, impacting investor confidence in both companies.
Risk Assessment
Risk Level: low — This is a routine amendment filing, not indicating any immediate or significant financial risk.
Analyst Insight
Investors should look for the specific changes in Biogen's beneficial ownership percentage of Denali Therapeutics within the full filing to understand the magnitude of the shift and its potential implications for both companies' future strategies or financial performance.
Key Players & Entities
- Biogen Inc. (company) — the reporting person filing the SC 13G/A
- Denali Therapeutics Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A
- 24823R105 (other) — the CUSIP number for Denali Therapeutics Inc. common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*' sections.
Who is the reporting person in this filing?
The reporting person is Biogen Inc., as indicated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC.' and 'Names of Reporting Persons. Biogen Inc.'
What is the subject company whose securities are being reported?
The subject company is Denali Therapeutics Inc., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc.' and 'DENALI THERAPEUTICS INC. (Name of Issuer)'.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the filing under 'December 31, 2023 (Date of Event Which Requires Filing of this Statement)'.
Under which rule of the Securities Exchange Act of 1934 is this Schedule filed?
This Schedule is filed under Rule 13d-1(c), as indicated by the checked box '☒ Rule 13d-1(c)' on the cover page.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 7.6 · Accepted 2024-02-12 19:07:55
Key Financial Figures
- $0.01 — INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
Filing Documents
- d589107dsc13ga.htm (SC 13G/A) — 38KB
- 0001193125-24-032401.txt ( ) — 40KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct. BIOGEN INC. By: /s/ Michael Dambach Name: Michael Dambach Title: Treasurer BIOGEN MA INC. By: /s/ Michael Dambach Michael Dambach Treasurer Date: February 12, 2024